

State of Connecticut
Regulation of
Department of Consumer Protection
Concerning
Palliative Use of Marijuana

The Regulation of Connecticut State Agencies are amended by adding Section 21a-408-12a as follows:

(NEW) Sec. 21a-408-12a. Additional Debilitating Medical Conditions

In accordance with the procedures set forth in section 21a-408a-12 of the Regulations of Connecticut State Agencies, the following medical conditions, medical treatments or diseases shall be added to the list of debilitating medical conditions:

- (1) Sickle cell disease;
- (2) Post laminectomy syndrome with chronic radiculopathy;
- (3) Severe psoriasis and psoriatic arthritis;
- (4) Amyotrophic lateral sclerosis;
- (5) Fabry disease;
- (6) Ulcerative colitis; and
- (7) Complex regional pain syndrome, Type 1 and Type II.

Statement of Purpose

This proposed new regulation establishes additional debilitating medical conditions for which the palliative use of medical marijuana is allowed. In accordance with the procedures set forth in Section 21a-408a-12 of the Regulations of Connecticut State Agencies, the Commissioner received written petitions to add debilitating conditions; the petitions were referred to the Board of Physicians and public hearings were held on November 26, 2014 for sickle cell disease, post laminectomy syndrome with chronic radiculopathy, and severe psoriasis and psoriatic arthritis. After having fully considered the testimony and documents made part of the record, on January 14, 2015, the Board of Physicians issued its written recommendation to the Commissioner to add sickle cell disease, post laminectomy syndrome with chronic radiculopathy, and severe psoriasis and psoriatic arthritis, and the Commissioner concluded that sickle cell disease, post laminectomy syndrome with chronic radiculopathy, and severe psoriasis and psoriatic arthritis should be added to the list of debilitating medical conditions by promulgating this regulation.

In accordance with the procedures set forth in Section 21a-408a-12 of the Regulations of Connecticut State Agencies, the Commissioner received written petitions to add debilitating conditions; the petitions were referred to the Board of Physicians and public hearings were held on March 11, 2015 for amyotrophic lateral sclerosis, Fabry disease, and ulcerative colitis. After having fully considered the testimony and documents made part of the record, on April 22, 2015, the Board of Physicians issued its written recommendation to the Commissioner concerning the addition of amyotrophic lateral sclerosis, Fabry disease, and ulcerative colitis to the list of debilitating conditions and the Commissioner concluded that amyotrophic lateral sclerosis, Fabry disease, and ulcerative colitis should be added to the list of debilitating medical conditions by promulgating this regulation.

In accordance with the procedures set forth in Section 21a-408a-12 of the Regulations of Connecticut State Agencies, the Commissioner received a written petition to add debilitating conditions; the petition was referred to the Board of Physicians and a public hearing was held on August 5, 2015 for complex regional pain syndrome. After having fully considered the testimony and documents made part of the record, on August 19, 2015, the Board of Physicians issued its written recommendation to the Commissioner concerning the addition of complex regional pain syndrome and the Commissioner concluded that complex regional pain syndrome should be added to the list of debilitating medical conditions by promulgating this regulation.